Novartis India to Acquire Pfizer's 'Minipress' Trademark for Rs 1,250 Crore
7 Articles
7 Articles
Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Trademarks
Novartis India has agreed to acquire Pfizer's 'Minipress' and 'Minipres' trademarks in India for INR 1,250 crore. Meanwhile, Pfizer Ltd announced it will discontinue the marketing and sale of Minipress XL following a global manufacturing halt by Pfizer Inc. Minipress XL is prescribed in India primarily for treating hypertension or high blood pressure. Novartis India Expands Portfolio With INR 1,250 Crore Acquisition of Pfizer's Minipress Tradema…
Novartis India to acquire Pfizer's 'Minipress' trademark for Rs 1,250 crore
Novartis India will acquire the Minipress and Minipres trademarks and related intellectual property from Pfizer for about ₹1,250 crore. Minipress XL, used for hypertension and benign prostatic hyperplasia, generated ₹228.6 crore in revenue as of July 2026, according to IQVIA data.
Novartis India to acquire Pfizer's ‘Minipress’ trademark for ₹1,250 crore
Novartis India Ltd on Monday announced that its Board of Directors has approved the acquisition of the trademarks 'Minipress' and 'Minipres' from Pfizer Inc. USA and Pfizer Products Inc. USA for a total consideration of approximately Rs 1,250 crore.
Novartis India to Buy Pfizer's Minipress Brand for Rs 1,250 Cr
Novartis India will acquire Pfizer’s Minipress and Minipres trademarks in India for Rs 1,250 crore, as Pfizer exits the hypertension drug. The approval came at a board meeting held on September 7, and covers both the trademarks registered in India along with certain related intellectual property rights tied to the...
Coverage Details
Bias Distribution
- 83% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium










